Cervical Cancer Screening Utilization and Associated Factors Among Women Aged 30 to 49 Years in Dire Dawa, Eastern Ethiopia.
Dire Dawa
Ethiopia
cervical cancer
screening utilization
Journal
Cancer control : journal of the Moffitt Cancer Center
ISSN: 1526-2359
Titre abrégé: Cancer Control
Pays: United States
ID NLM: 9438457
Informations de publication
Date de publication:
Historique:
entrez:
9
10
2020
pubmed:
10
10
2020
medline:
30
6
2021
Statut:
ppublish
Résumé
Cervical cancer is a public health problem and one of the leading causes of death in women worldwide. In Ethiopia, the government expands cervical cancer screening centers and recommends services to age-eligible and high-risk groups of women. However, evidence indicates that the utilization of services among eligible and high-risk women in the country has remained very low, and data are scarce in Dire Dawa. Therefore, this study aimed to assess cervical cancer screening service utilization and associated factors among women aged 30 to 49 years in Dire Dawa, eastern Ethiopia. A facility-based cross-sectional study was undertaken in Dire Dawa from February 01 to March 01, 2017. Only two facilities provided the screening service in Dire Dawa Administration. Six- hundred and one women aged 30 to 49 years were selected using a systematic sampling method. Data were collected using a pretested face-to-face interview administered questionnaire. Data were entered using EpiData 3.1, and analyzed using the Statistical Package for Social Science Version 21. Multivariable logistic regression was used to examine the factors associated with cervical cancer screening utilization. An adjusted odds ratio (AOR) with a 95% confidence interval (CI) was used, and a p-value <0.05 was considered statistically significant. In this study, the magnitude of cervical cancer screening service utilization was 4.0% (95% CI: 2.5-5.7). The factors associated with cervical cancer screening service utilization were older age (AOR = 4.2; 95% CI:1.3-13.8), attending private health facilities (AOR = 8.9; 95% CI: 2.8-28.0), being employed (AOR = 3.3; 95% CI: 1.3-8.8), visiting the gynecology departments (AOR = 3.8; 95% CI: 1.5-9.8), being knowledgeable (AOR = 4.8; 95% CI: 1.5-15.5), being counseled by health professionals (AOR = 4.1; 95% CI: 1.5-11.3), and user's of family planning (AOR = 4.9; 95% CI: 1.2-20.0). The magnitude of cervical cancer screening utilization was very low. Hence, to improve the screening service utilization of cervical cancer, a campaign on community awareness, strengthening service linkage among departments, expansion of the centers for cervical cancer screening, and promotion of family planning method utilization are recommended.
Sections du résumé
BACKGROUND
BACKGROUND
Cervical cancer is a public health problem and one of the leading causes of death in women worldwide. In Ethiopia, the government expands cervical cancer screening centers and recommends services to age-eligible and high-risk groups of women. However, evidence indicates that the utilization of services among eligible and high-risk women in the country has remained very low, and data are scarce in Dire Dawa. Therefore, this study aimed to assess cervical cancer screening service utilization and associated factors among women aged 30 to 49 years in Dire Dawa, eastern Ethiopia.
METHODS
METHODS
A facility-based cross-sectional study was undertaken in Dire Dawa from February 01 to March 01, 2017. Only two facilities provided the screening service in Dire Dawa Administration. Six- hundred and one women aged 30 to 49 years were selected using a systematic sampling method. Data were collected using a pretested face-to-face interview administered questionnaire. Data were entered using EpiData 3.1, and analyzed using the Statistical Package for Social Science Version 21. Multivariable logistic regression was used to examine the factors associated with cervical cancer screening utilization. An adjusted odds ratio (AOR) with a 95% confidence interval (CI) was used, and a p-value <0.05 was considered statistically significant.
RESULTS
RESULTS
In this study, the magnitude of cervical cancer screening service utilization was 4.0% (95% CI: 2.5-5.7). The factors associated with cervical cancer screening service utilization were older age (AOR = 4.2; 95% CI:1.3-13.8), attending private health facilities (AOR = 8.9; 95% CI: 2.8-28.0), being employed (AOR = 3.3; 95% CI: 1.3-8.8), visiting the gynecology departments (AOR = 3.8; 95% CI: 1.5-9.8), being knowledgeable (AOR = 4.8; 95% CI: 1.5-15.5), being counseled by health professionals (AOR = 4.1; 95% CI: 1.5-11.3), and user's of family planning (AOR = 4.9; 95% CI: 1.2-20.0).
CONCLUSION
CONCLUSIONS
The magnitude of cervical cancer screening utilization was very low. Hence, to improve the screening service utilization of cervical cancer, a campaign on community awareness, strengthening service linkage among departments, expansion of the centers for cervical cancer screening, and promotion of family planning method utilization are recommended.
Identifiants
pubmed: 33034204
doi: 10.1177/1073274820958701
pmc: PMC7791449
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1073274820958701Références
N Am J Med Sci. 2015 Mar;7(3):104-13
pubmed: 25839002
BMC Public Health. 2019 Aug 14;19(1):1102
pubmed: 31412831
PLoS One. 2016 Mar 10;11(3):e0149908
pubmed: 26963098
BMC Health Serv Res. 2015 Dec 15;15:552
pubmed: 26666242
PLoS Med. 2008 Jun 17;5(6):e132
pubmed: 18563963
BMJ Open. 2017 Apr 3;7(4):e013868
pubmed: 28373252
Singapore Med J. 2013 Mar;54(3):163-8
pubmed: 23546031
BMC Womens Health. 2015 Nov 24;15:106
pubmed: 26597844
Asian Pac J Cancer Prev. 2014;15(8):3753-6
pubmed: 24870788
Asian Pac J Cancer Prev. 2018 Mar 27;19(3):825-831
pubmed: 29582641
BMJ Glob Health. 2019 May 13;4(3):e001452
pubmed: 31179040
Asian Pac J Cancer Prev. ;18(7):1751-1763
pubmed: 28749101
PLoS One. 2013 Dec 20;8(12):e84519
pubmed: 24376818
BMC Womens Health. 2018 Jun 7;18(1):87
pubmed: 29879969
BMC Cancer. 2013 Jan 02;13:2
pubmed: 23282173
BMC Public Health. 2008 Jul 30;8:262
pubmed: 18664298
HIV Med. 2017 Mar;18(3):181-195
pubmed: 28967199
PLoS One. 2016 Feb 19;11(2):e0149696
pubmed: 26894270
Gynecol Oncol. 2005 Dec;99(3 Suppl 1):S201-2
pubmed: 16419208